Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia

Other

Pipeline Programs↗

Distinct drugs in development (Preclinical–Phase 3)

Indications↗

Distinct diseases across all programs

Clinical Trials↗

All sponsored trials (all statuses)

Pipeline

Pipeline Snapshot

By Phase

1 drugs in development

Phase 21

By Therapeutic Area

top 1

Infectious Disease

1100%

R&D Momentum

38/100

Pipeline Velocity

19/100

Trial Completion Rate

100/100

Pipeline Concentration

100/100

Pipeline Freshness

86/100

Activity

Recent Activity

Last 14 days

Jul 9, 2026

Completed

Oral and Neuro-Penetrative Alternative Antibiotics for Patients With Syphilis

Jul 8, 2026

Recruiting

Characterization of Vaccine-induced Responses Against Monkeypox (MoVIHvax) An Observational Prospective Cohort Study

Jul 7, 2026

Completed

Exploratory Phase 2 Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Safety and Impact on HIV-1 Reservoir of Baricitinib in Virologically Suppressed People With HIV-1

Earlier

Jun 24, 2026TrialRepurposing Clinically Approved Drugs for Yaws With an Insight Into the Cutaneous Ulcer Disease Syndrome (Trep-AByaws)

Nov 3, 2025TrialUlcer Plants: Highly Accessible Plant Antiseptics for Use in Remote Areas of PNG - Second Trial

Sep 1, 2025TrialSafety and Effectiveness of a Remdesivir Treatment to Prevent Severe COVID-19 in Kidney Transplant Patients

Feb 7, 2025TrialStudy to Evaluate the Efficacy and Safety of Plitidepsin in Adults with Post-COVID-19 Condition (PCC)

Oct 28, 2024TrialA Single-center, Self-controlled, Prospective Case Series Pilot Study to Assess the Effect of Lamivudine (3TC) on Neurocognitive Impairment Biomarkers and Type-I IFN (Interferon)-Stimulated Genes in the Plasma of Patients With Mild Cognitive Impairment (MCI)

3 more events

Oct 4, 2024TrialUlcer Plants: Highly Accessible Plant Antiseptics for Use in Remote Areas of PNG

Sep 26, 2023TrialImplementation of Out-of-HOspital Administration of the Long-Acting Cabotegravir+Rilpivirine

Sep 12, 2022TrialBreak-through Infection Following Mpox vaccinatIon

Details

Company Info

Company Overview

—

Mkt Cap

—

Revenue

—

Cash

Pipeline

Drug Pipeline

Indication

Preclinical

Phase 1

Phase 2

Phase 3

Approved

Infectious Disease

COVID-19

Plitidepsin /day

Infectious Disease

COVID-19

Plitidepsin /dayPhase 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)